Biogen Inc. stock reacts to Leqembi Pen approval and fresh guidance

Published on 09/20/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen Inc. stock closed at USD 215.50 on Nasdaq on September 18, 2026, amid investor reaction to Japan’s approval of the Alzheimer therapy Leqembi Pen. The company now guides 2026 non-GAAP EPS between USD 15.25 and USD 16.25 as total revenue is expected to decline mid-single digits versus 2025.

Fotorealistisches Biotech-Labor in Cambridge MA mit Forscherin am Mikroskop und Blick auf den Charles River — Biogen Inc. Neurowissenschaftslabor in Cambridge MA zeigt Forscherin bei Gehirngewebeanalyse unter Mikroskop ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. stock (ISIN US09062X1037) closed at USD 215.50 on Nasdaq on September 18, 2026, down 1.62% from the prior session as investors digested fresh guidance and the regulatory approval of the Alzheimer therapy Leqembi Pen in Japan.

Leqembi Pen approval supports Alzheimer portfolio

According to Ad-hoc-news on September 19, 2026, Biogen and its partner Eisai announced that the subcutaneous Leqembi Pen formulation has been approved in Japan for the treatment of early-stage Alzheimer’s disease, expanding the options beyond the original intravenous form.

The same report cites a release from JCN Newswire dated September 18, 2026, in which Biogen and Eisai emphasize that Leqembi Pen contains the monoclonal antibody lecanemab and is designed to reduce clinic time and broaden access by allowing subcutaneous administration, a strategic move that strengthens Biogen’s neurology franchise in the Alzheimer segment.

For investors, the Japanese approval is significant because Leqembi is one of the leading disease-modifying therapies aimed at slowing cognitive decline in early Alzheimer’s, and a more convenient delivery form can materially increase the addressable patient population and long-term revenue potential compared with the original infusion-only regimen.

Fresh 2026 guidance and earnings outlook

In parallel with the regulatory progress, Biogen has updated its financial guidance for the current year 2026, giving the market a clearer view of profitability and top-line trends.

According to StockTitan summarizing a recent Form 8-K, Biogen now expects non-GAAP diluted EPS between USD 15.25 and USD 16.25 for full year 2026, and anticipates that total revenue will decline by a mid-single-digit percentage versus 2025.

The same filing indicates that Biogen expects gross margin and combined non-GAAP research and development plus selling, general and administrative expenses to remain roughly consistent year over year, signaling that the company aims to protect profitability despite the anticipated revenue decline.

The mid-single-digit revenue decline versus 2025 means that, for example, a 5 percent drop on a hypothetical 2025 revenue base of USD 10.0 billion would translate into a 2026 revenue level around USD 9.5 billion; for investors, such quantified guidance underscores that Biogen is managing through legacy product headwinds while investing in growth areas like Alzheimer therapies.

Analyst targets and valuation context

Biogen’s updated guidance and the Leqembi Pen approval are reflected in the valuation and analyst views that the market is currently using as reference.

Per data from MarketBeat, Biogen shares closed at USD 215.50 on Nasdaq on September 18, 2026, with a 52-week range between USD 135.39 and USD 225.80, and a market capitalization of USD 31.84 billion as of that closing price.

The same overview reports an average analyst price target of USD 230.14, compared with the USD 215.50 closing price; this implies potential upside of about 6.8 percent if the consensus scenario is realized, placing the stock modestly below the collective target band while still near the top end of its 52-week trading corridor.

MarketBeat also notes that Biogen carries a consensus rating of Moderate Buy, based on a mix of 1 strong buy, 18 buy, 13 hold and 1 sell recommendations, underscoring that while opinions differ, the majority of covering analysts expect the shares to perform positively over the medium term in light of the Alzheimer pipeline and the clarified earnings trajectory.

Risk factors around Alzheimer therapies

The opportunity in Alzheimer’s disease for Biogen is accompanied by notable medical and regulatory risks, which investors need to weigh against the potential rewards.

As reported by Russpain on September 20, 2026, clinical trials such as Clarity AD have shown that lecanemab reduced cognitive decline by about 27 percent over 18 months, while other agents like donanemab achieved reductions of up to 35 percent in certain patient subgroups, demonstrating that disease-modifying therapies can slow progression but do not cure Alzheimer’s.

The same article highlights that these treatments require close monitoring for amyloid-related imaging abnormalities, including brain swelling and microhemorrhages, and that reimbursement decisions in key markets such as Spain remain unresolved as of September 2026, illustrating how safety concerns and payer scrutiny could limit real-world uptake even after regulatory approvals.

For Biogen, therefore, the Japanese approval of Leqembi Pen is an important step, but the long-term commercial trajectory will depend on how quickly health systems adopt blood-based diagnostics, how comfortable physicians become with managing safety risks, and how reimbursement frameworks evolve in major geographies.

Biogen Inc. stock price and trading details

On the primary listing venue Nasdaq, Biogen Inc. stock with ticker BIIB finished the session on September 18, 2026, at USD 215.50, representing a decline of 1.62 percent compared with the prior closing price, with trading volume of 2,630,000 shares and a 52-week range between USD 135.39 and USD 225.80, while the market capitalization stood at USD 31.84 billion as of that date.